Rich Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapies in oncology, with initial concentration in treating AML, Myelodysplastic
Syndromes (MDS) and Hodgkin's Lymphoma.
The innovative study titled, Risk of acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS) after adjuvant chemotherapy (CT) for early breast cancer (BC) in the community setting, shows that adjuvant chemotherapy did not increase a patient s risk of AML/MDS compared with those who did not receive chemotherapy.
T9YFkNVulPI) Robin Roberts is a breast cancer survivor, and she told Monday's audience she has another medical battle to fight: a rare blood disorder known as myelodysplastic
syndrome, or MDS.
syndromes (MDS) encompass a heterogeneous group of clonal haematopoietic disorders characterised by chronic and progressive cytopenias resulting from ineffective haematopoiesis.
The National Institute for Health and Clinical Excellence (Nice) said it has ruled in draft guidance that azacitidine could not be prescribed on the NHS for the treatment of a number of myelodysplastic
The study showed that patients with advanced acute myeloid leukemia or high-risk myelodysplastic
syndrome - a pre-leukemic condition - experienced a remission with the help of combination of low-intensity chemotherapy, targeted radiation delivery by an antibody and a stem-cell transplant.
Background & objectives: Myelodysplastic
syndrome (MDS) represents a group of clonal haematological disorders characterized by progressive cytopenia reflecting defects in erythroid, myeloid and megakaryocytic maturation.
The lesion may precede or occur concurrently with acute or chronic myeloid leukemia or the other types of myeloproliferative or myelodysplastic
LONDON, March 2 /PRNewswire/ -- The Myelodysplastic
Syndromes (MDS) Foundation is pleased to support the licensed use of VIDAZA in the United Kingdom and Ireland to treat a subset of patients with intermediate-2 and higher-risk MDS, chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML with 20-30% blasts).
A new scoring system for a form of leukemia known as myelodysplastic
syndrome (MDS) identifies patients who appear to have a low-risk form of the disease, but actually have poor prospects of survival, report researchers at the University of Texas M.
Nevertheless, physician Simone Boehrer of the Gustave-Roussy Institute in Villejuif, France, and her colleagues tested erlotinib in a lab dish on bone marrow cells taken from 10 patients with either acute myeloid leukemia or a precancerous blood disorder called myelodysplastic
Is this product also recommended for myelodysplastic
syndrome (MDS) when these patients depend on multiple transfusions over a long time?